QURE UNIQURE NV

uniQure to Participate in Multiple Upcoming Industry Conferences in September

uniQure to Participate in Multiple Upcoming Industry Conferences in September

LEXINGTON, Mass. and AMSTERDAM, Sept. 07, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences:

  • Citi’s 16th Annual BioPharma Virtual Conference, September 8 - 10, 2021



    • Members of uniQure’s management team, including , chief executive officer, will participate in virtual one-on-one investor meetings throughout the day on Thursday, September 9.



  • Wells Fargo 2021 Virtual Healthcare Conference, September 9 - 10, 2021



    • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Friday, September 10.



    • A fireside chat with Matt Kapusta will take place the same day from 12:00 to 12:30 p.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the section of the uniQure website.



  • H.C. Wainwright 23rd Annual Global Investment Conference, September 13 - 15, 2021



    • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Wednesday, September 15.



    • A pre-recorded fireside chat with Matt Kapusta will be available on September 13th through H.C. Wainwright or can accessed through the link displayed in the section of the uniQure website.



  • SVB Leerink CybeRx Series: Neuromuscular, Rare Disease & Genetic Medicines Summit, September 22 - 23, 2021



    • Members of uniQure’s management team including president of Research & Development will participate in virtual one-on-one investor meetings throughout the day on Thursday, September 23.



  • 2021 Cantor Virtual Global Healthcare Conference, September 27 - 30, 2021



    • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Monday, September 27.



    • Ricardo Dolmetsch will participate in a fireside chat the same day at 9:20 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the section of the uniQure website.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a of proprietary gene therapies to treat patients with severe genetic diseases of the central nervous system (CNS) and liver, including clinical programs in hemophilia B and Huntington's disease and preclinical candidates in Fabry disease, spinocerebellar ataxia Type 3, temporal lobe epilepsy, Alzheimer’s, Parkinson’s, and ALS.

uniQure Contacts:

FOR INVESTORS: FOR MEDIA:
   
Maria E. CantorChiara RussoTom Malone
Direct: 339-970-7536Direct: 617-306-9137Direct: 339-970-7558


EN
07/09/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on UNIQURE NV

 PRESS RELEASE

uniQure Announces Second Quarter 2025 Financial Results and Highlights...

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress ~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 topline three-year data in September 2025 ~ ~ Presented case study from first participant treated with AMT-260 for refractory mesial temporal lobe epilepsy showing 92% seizure reduction with no serious adverse events through first five months of follow u...

 PRESS RELEASE

uniQure to Announce Second Quarter 2025 Financial Results

uniQure to Announce Second Quarter 2025 Financial Results uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET LEXINGTON, Mass. and AMSTERDAM, July 22, 2025 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second quarter 2025 financial results before market open on Tuesday, July 29, 2025. Management will then host a conference call at 8:30 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure’s website at , and following th...

 PRESS RELEASE

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and ...

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer ~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Kylie O’Keefe as Chief Customer and Strategy Officer, effective June 6, 2025. In this role, Ms. O’Keefe will lead the development and execution of uniQure’s global commercialization strate...

 PRESS RELEASE

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease ~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today provided a regulatory update on AMT-130, its investigational gene therapy for the treatment of Huntington’s disease. Following recent Type B meetings and...

 PRESS RELEASE

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-2...

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) ~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy Therapies & Diagnostics Development Symposium (ETDD) ~ LEXINGTON, Mass. and AMSTERDAM, May 29, 2025 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the presenta...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch